Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecozotan in mild to moderate Alzheimer's disease
NCT00277810Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2006
- Primary completion
- Jun 2008
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of lecozotan in Alzheimer's disease (AD) (4 arms), sponsored by Pfizer. Primary endpoints: Alzheimer's Disease Assessment Scale-cognitive subscale at 24 weeks, Clinician's Interview-Based Impression of Change plus caregiver input at 24 weeks and 1 more. Started Mar 2006; status: completed.
02
Drugs
lecozotan
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00277810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277810.